Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies

TY - JOUR

T1 - Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies

AU - Borch, Troels H

AU - Donia, Marco

AU - Andersen, Mads H

AU - Svane, Inge M

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/9/9

Y1 - 2015/9/9

N2 - Physiologically, the programmed death 1 (PD-1) pathway is involved in limiting the killing of bystander cells during an infection and controlling autoimmunity. However, cancers exploit this system to avoid immune killing, and PD-1 ligand 1 and 2 (PD-L1 and PD-L2) expression on tumor cells, as well as PD-1 expression on tumor-infiltrating lymphocytes, have shown to be negative prognostic factors. Promising clinical results have been obtained by PD-1 pathway blockade in a range of cancers while still maintaining a manageable toxicity profile, and two anti-PD-1 antibodies are now approved by the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma. As already shown with nivolumab and ipilimumab, the combination of PD-1 pathway blockade with other anticancer agents holds promise in the form of additive synergistic anticancer effects.

AB - Physiologically, the programmed death 1 (PD-1) pathway is involved in limiting the killing of bystander cells during an infection and controlling autoimmunity. However, cancers exploit this system to avoid immune killing, and PD-1 ligand 1 and 2 (PD-L1 and PD-L2) expression on tumor cells, as well as PD-1 expression on tumor-infiltrating lymphocytes, have shown to be negative prognostic factors. Promising clinical results have been obtained by PD-1 pathway blockade in a range of cancers while still maintaining a manageable toxicity profile, and two anti-PD-1 antibodies are now approved by the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma. As already shown with nivolumab and ipilimumab, the combination of PD-1 pathway blockade with other anticancer agents holds promise in the form of additive synergistic anticancer effects.

U2 - 10.1016/j.drudis.2015.07.003

DO - 10.1016/j.drudis.2015.07.003

M3 - Review

C2 - 26189934

SN - 1359-6446

VL - 20

SP - 1127

EP - 1134

JO - Drug Discovery Today: BIOSILICO

JF - Drug Discovery Today: BIOSILICO

IS - 9

ER -